Executive Summary
Efgartigimod is the first-in-class FcRn-blocking Fc fragment approved for gMG and CIDP, with $4.2B in 2025 net sales and 6 upcoming Phase 3 readouts across autoimmune indications.
Efgartigimod (VYVGART / VYVGART Hytrulo)
FcRn · Fc fragment (antibody fragment)
Mechanism of Action[Corp '26 S20]
TypeFcRn blocker (Fc fragment)
DescriptionEfgartigimod is an engineered Fc fragment that binds FcRn with high affinity, blocking its ability to recycle IgG antibodies, accelerating IgG degradation including pathogenic autoantibodies.
DifferentiationFirst-in-class Fc fragment; first and only FcRn blocker approved in MG; available as IV (VYVGART) and SC with hyaluronidase (VYVGART Hytrulo PFS); autoinjector estimated 2027
Target Biology[Corp '26 S11]
FcRn is a receptor that rescues IgG antibodies from degradation, keeping their levels high in the blood. By blocking FcRn, efgartigimod accelerates breakdown of pathogenic IgG autoantibodies, reducing the autoimmune attack on the body's tissues.
Clinical Data
ADAPT Oculus[Corp '26 S26]
Phase 3 Readout expected 1Q 2026Endpoints
| Endpoint | Result | ||
|---|---|---|---|
Primary: MGII (novel primary endpoint)[Corp '26 S26] |
None | ||
ALKIVIA[Corp '26 S26]
Phase 3 Readout expected 3Q 2026Endpoints
| Endpoint | Result | ||
|---|---|---|---|
Primary: TIS (Total Improvement Score) composite[Corp '26 S26] |
None | ||
ADVANCE NEXT[Corp '26 S26]
Phase 3 Readout expected 4Q 2026Endpoints
| Endpoint | Result | ||
|---|---|---|---|
Primary: Cumulative platelet count[Corp '26 S26] |
None | ||
UNITY[Corp '26 S26]
Phase 3 Readout expected 2H 2027Endpoints
| Endpoint | Result | ||
|---|---|---|---|
Primary: Not specified (described as 'challenging primary endpoint')[Corp '26 S26] |
None | ||
UplighTED Phase 3 (TED) — DISCONTINUED
Phase 3 Discontinued for futility (Dec 15, 2025) n=123 per study (246 total across two studies)Endpoints
| Endpoint | Result | ||
|---|---|---|---|
Primary: Proptosis responders at Week 24 Percentage of participants who were proptosis responders at Week 24 |
FAILED — IDMC recommended stopping for futility after pre-specified interim analysis. Treatment unlikely to meet primary endpoint. | ||
Change in proptosis measurement from baseline to Week 24 |
Pending | ||
Change in GO-QoL total score from baseline to Week 24 |
Pending | ||
Percentage with diplopia resolution at Week 24 |
Pending | ||
Safety
Favorable safety and tolerability profile. No new safety signals identified.
ADAPT-SERON (Seronegative gMG)
Phase 3 Completed — positive. sBLA accepted by FDA with Priority Review. PDUFA May 10, 2026. n=119 (AChR-Ab seronegative gMG: MuSK+, LRP4+, and triple seronegative subtypes)Endpoints
| Endpoint | Result | ||
|---|---|---|---|
Primary: MG-ADL total score change from baseline to Day 29 (Part A) MG-ADL is a validated measure evaluating functional impact on daily activities: speaking, chewing, swallowing, breathing, limb strength |
MET — statistically significant improvement (p=0.0068). Mean improvement of 3.35 points in MG-ADL total score at Week 4 (clinically meaningful). | ||
QMG score |
Improvements observed across subsequent treatment cycles in overall population and all subgroups | ||
MG-QoL 15r |
Pending | ||
MGC |
Pending | ||
EQ-5D-5L VAS |
Pending | ||
Safety
Well-tolerated. Safety profile consistent with established VYVGART profile in AChR-Ab seropositive gMG and other indications. No new safety concerns identified.
Investment Analysis
Satya Bio Analysis — estimates based on public data and analyst judgment, not sourced from company materials
Bull Case
| Thesis Point | Supporting Evidence | Confidence |
|---|---|---|
| Market-leading franchise with $4.2B revenue and 90% YoY growth | FY 2025 product net sales (slide 7) | High |
| Label expansion to 60K US addressable MG patients by 2030 | US addressable patient waterfall (slide 12) | Medium |
| CIDP blockbuster validates multi-indication strategy | Blockbuster status as of 3Q 2025 (slide 11) | High |
Bear Case
| Risk | Evidence | Mitigating Factors |
|---|---|---|
| Novel Phase 3 endpoints create binary risk across 4 readouts in 2026 | MGII, TIS, cumulative platelet, challenging endpoint (slide 26) | — |
| Rheumatology expansion requires new commercial infrastructure | Current prescriber base is neurology-focused (slide 11) | — |
Key Debates
| Question | Bull View | Bear View | Resolution Catalyst |
|---|---|---|---|
| Will the MGII novel primary endpoint succeed in Ocular MG? | ADAPT ocular domain data and real-world case reports support endpoint | Novel endpoints carry inherent risk | 1Q 2026 Phase 3 readout |
Market Opportunity
Total Addressable Market
gMG: 60K US patients by 2030 (17K at launch); CIDP: 42K diagnosed (12K at launch); ITP: significant Japan market; Myositis, Sjogren's, Ocular MG, seronegative gMG all expansion
Patient Population
~19,000 patients on VYVGART globally (Jan 2026). 15+ severe autoimmune diseases being studied.
Unmet Need: 70% of new MG patients coming directly from orals (earlier treatment paradigm adoption). 12,000 CIDP patients remain inadequately controlled on SOC in US.
Catalysts & Upcoming Events
| Event | Timing | Importance | Key Metrics to Watch | Consensus |
|---|---|---|---|---|
| Seronegative gMG PDUFA decision date | May 10, 2026 | critical | FDA Priority Review. ADAPT-SERON met primary (p=0.0068, MG-ADL -3.35pts). If approved: broadest MG label, adds ~20% of gMG population (MuSK+, LRP4+, triple seronegative). First-ever treatment for LRP4+ and triple seronegative patients. Launch expected by end 2026. | — |
| Ocular MG Phase 3 readout (ADAPT Oculus) | 1Q 2026 | critical | MGII novel primary endpoint; first and only development in Ocular MG | — |
| AChR- gMG (seronegative) approval decision | By end of 2026 | critical | Broadest MG label (MuSK+, LRP4+, triple seronegative) | — |
| Myositis Phase 3 readout (ALKIVIA) | 3Q 2026 | critical | TIS composite endpoint; 70K US prevalence | — |
| ITP Phase 3 readout (ADVANCE NEXT) | 4Q 2026 | critical | Cumulative platelet count in difficult-to-treat patients | — |
| Sjogren's Phase 3 readout (UNITY) | 2H 2027 | high | Challenging primary endpoint; 330K US prevalence | — |
| UplighTED Phase 3 TED — DISCONTINUED for futility | Dec 15, 2025 (completed — FAILED) | high | IDMC stopped trials at interim for futility. Proptosis endpoint not met. Removes ~$550M peak sales. Data at future meeting. | — |
| ADAPT-Forward combination study (efgartigimod + empasiprubart) in AChR+ gMG | Ongoing (started 2025) | medium | First combination study; could show deeper efficacy and differentiate from single-agent FcRn competitors | — |